Expert Interviews

David Pope, PharmD, Chief Pharmacy Officer at XiFin, discussed pharmacy benefit managers and their impact on value-based care within pharmacies.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Stevie Veach of MercyOne Pharmacy in Dubuque, Iowa, talked about her pharmacy’s offerings and how they serve her community’s patients.

Drug Topics sat down with Adam J. James, PharmD, to discuss learnings from his extensive experience at Rite Aid.

In an interview with Drug Topics, TaQuina Warren, PharmD, discussed what it means to serve her community and how she has garnered a reputation within her profession.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Anthony Minniti of Bell Pharmacy in Camden, New Jersey, discussed pharmacy in his community and the challenges that come with it.

Drug Topics sat down with Benjamin Jolley, PharmD, of Jolley’s Compounding Pharmacy, to discuss the pharmacy industry and his experience in a myriad of roles within the profession.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Lea Wolsoncroft of Remedies Pharmacy in Hoover, Alabama, discussed what is going on in her pharmacy practice.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Henry and Jade Ranger of The Prescription Shoppe in Williamsburg, Virginia, discussed their practice and what it’s like operating a business together.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the role his company plays in the ongoing issue of rising drug prices.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the federal level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

Kristen Hartzell, PharmD, Vice President of Clinical Services, RedSail Technologies, sat down with Drug Topics to discuss the RxCash+ tool designed to achieve fairer pricing on cash prescriptions for pharmacies and patients.

Dana Krug, Senior Vice President of Cold Chain Fulfillment at Phononic, explained the current state of his company’s cooling technology and the common trends of temperature control throughout the industry.

Dana Krug, Senior Vice President of Cold Chain Fulfillment at Phononic, discussed the importance of cooling medications in the rising heat of the summer months.

Dana Krug, Senior Vice President of Cold Chain Fulfillment at Phononic, discussed the role his company’s technology plays in the pharmaceutical industry.

Jeremy Cundiff, PharmD, co-owner of Professional Pharmacy Group, joined Drug Topics to discuss Return Solutions and the company’s Rx Returns process.

Drug Topics sat down with Sandra Canally, RN, founder and CEO of The Compliance Team, and Kara Benson, PharmD, long-term care director of Lewis Drug Inc, to discuss the future of LTC pharmacy.

The specialty drug market has exploded in the last few decades.

As medication experts, pharmacists can advocate to organizational decision makers around the benefits of biosimilars.

Data from 2024 are being used as a way to predict what changes may be on the way for 2025.

The market is sensitive to both upstream and downstream pressures that impact drug pricing.

The specialty drug market has exploded, and will continue to grow across sectors such as oncology and neurology.

A lack of clarity around certain provisions of the Inflation Reduction Act has presented challenges to payers.

A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.

Understanding the goals of each party is the first step to a successful collaboration.

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

Collaboration between health system specialty pharmacies and manufacturers can benefit patients in the long run.

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.